News

In-Kind contributions to Additional Activities (IKAAs) are health research and capacity development projects that EDCTP Association member countries directly fund and manage with their own national funding and align with Global Health EDCTP3 goals.

Researchers and institutions from African Lusophone countries are making an increasingly important contribution to Global Health EDCTP3, already taking part in 25% of the project portfolio, a substantial increase compared to previous EDCTP Programme iterations.

From a child-friendly deworming pill to a simpler treatment for a deadly brain infection, EDCTP-funded trials have changed WHO recommendations. Now Global Health EDCTP3 is putting that experience into practice by joining the Global Clinical Trials Forum (GCTF).

This feature is the second in a series highlighting EDCTP-supported experts driving progress across global health. It showcases another ten influential figures whose work has been enabled through EDCTP fellowships, research projects and capacity-strengthening initiatives.

Madrid, Zaragoza and Barcelona will bring together international experts to discuss strategies for addressing health challenges in a globalised world.

Global Health EDCTP3 recorded a year of significant growth and impact in 2025, expanding its research portfolio, mobilising unprecedented partner investments and reinforcing its role as a leading global health partnership between Europe and Africa.

Global Health EDCTP3 is activating a €4 million emergency funding mechanism to support research activities addressing the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of the Congo (DRC) and Uganda.

The 13th EDCTP Forum will bring together researchers, policymakers, and funders to reinforce scientific collaboration, forge new partnerships and advance responses to shared health challenges.

New collaboration will support research on respiratory infections, infectious and non-communicable diseases, and strengthen international scientific cooperation.

Global Health EDCTP3 is investing €40 million to advance vaccines against dengue and chikungunya, two mosquito-borne viruses that are steadily expanding their reach.